(Press-News.org) In the U.S., there are nearly 300,000 children with juvenile arthritis and other rheumatic illnesses according to estimates from the American College of Rheumatology (ACR). For pediatric patients with systemic juvenile idiopathic arthritis (JIA), effective treatment for this disabling disease is imperative. New treatment recommendations that guide physicians caring for children with systemic JIA are now published in the ACR journals, Arthritis & Rheumatism and Arthritis Care & Research.
Systemic JIA is defined by the International League of Associations for Rheumatology as arthritis in one or more joints for at least six weeks in children sixteen years of age or younger. The arthritis is accompanied or preceded by fever for at least two-weeks that is daily ("quotidian") for at least 3 of those days, with one or more of the following symptoms: red rash (evanescent erythematous rash), enlarged liver, spleen or lymph nodes, and inflammation of the tissue lining (serositis) of the lungs, heart, or stomach. Medical evidence suggests that systemic JIA accounts for 4% to 15% of all JIA cases.
Each year the ACR reviews its current guidelines to ensure that they are up to date. In 2012, the ACR determined that an update to the 2011 JIA recommendations—specifically for treatment of systemic JIA—was needed. A new team that included researchers who worked on the original JIA guideline was assembled to develop the 2013 update. Investigators, led by Dr. Pamela Weiss from Children's Hospital of Philadelphia in Pennsylvania and Dr. Sarah Ringold from the Seattle Children's Hospital in Washington, conducted a systematic review of medical literature through January 2013.
The new recommendations for systemic JIA are based upon more than 1,200 clinical scenarios and include recommendations for use of the following medications:
Non-steroidal anti-inflammatory drugs (NSAIDs)
Glucocorticoids
Methotrexate
Leflunomide
Intravenous immunoglobulin (IVIG)
Calcineurin inhibitors
Tumor necrosis factor alpha (TNFα) inhibitors
Abatacept
Rituximab
Anakinra
Canakinumab *
Rilonacept *
Tocilizumab *
*New addition to the 2013 update
They include treatment options for patients with and without active systemic disease, along with varying degrees of inflammation of the joint lining (synovitis), as well as recommendations for repeat TB screening for JIA patients receiving biologics. Dr. Weiss concludes, "The 2013 recommendations address specific disease characteristics and reflect the commitment to enhancing care of children with systemic JIA."
###
This work was funded by the American College of Rheumatology, and investigators' time was supported in part by grants from the National Institute of Arthritis and Musculoskeletal and Skin Disease, NIH (grant1-K23-AR059749-01A) and the Agency for Healthcare Research and Quality (grant K12HS019482).
This study is published in Arthritis Care & Research and Arthritis & Rheumatism. Media wishing to receive a PDF of this article may contact sciencenewsroom@wiley.com.
Full citation: "2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis. Recommendations for the Medical Therapy of Children with Systemic Juvenile Idiopathic Arthritis and Tuberculosis Screening Among Children Receiving Biologic Medications." Sarah Ringold, Pamela F. Weiss, Timothy Beukelman, Esi Morgan DeWitt, Norman T. Ilowite, Yukiko Kimura, Ronald M. Laxer, Daniel J. Lovell, Peter A. Nigrovic, Angela Byun Robinson and Richard K. Vehe. Arthritis & Rheumatism (DOI: 10.1002/art.38092). Arthritis Care & Research (DOI: 10.1002/acr.22087); Published Online: September 24, 2013.
URL Upon Publication: http://doi.wiley.com/10.1002/art.38092 and http://doi.wiley.com/10.1002/acr.22087
About the Author: To arrange an interview with Dr. Ringold, please contact press@seattlechildrens.org. Media wishing to speak with Dr. Weiss may contact Jennifer Long at longj@email.chop.edu or +1 215-590-2105.
About the Journals
Arthritis & Rheumatism is an official journal of the American College of Rheumatology (ACR) and covers all aspects of inflammatory disease. The American College of Rheumatology (http://www.rheumatology.org) is the professional organization whose members share a dedication to healing, preventing disability, and curing the more than 100 types of arthritis and related disabling and sometimes fatal disorders of the joints, muscles, and bones. Members include practicing physicians, research scientists, nurses, physical and occupational therapists, psychologists, and social workers. The journal is published by Wiley on behalf of the ACR. For more information, please visit http://wileyonlinelibrary.com/journal/art.
Arthritis Care & Research is an official journal of the American College of Rheumatology (ACR), and the Association of Rheumatology Health Professionals (ARHP), a division of the College. Arthritis Care & Research is a peer-reviewed journal that publishes both original research and review articles that promote excellence in the clinical practice of rheumatology. Relevant to the care of individuals with arthritis and related disorders, major topics are evidence-based practice studies, clinical problems, practice guidelines, health care economics, health care policy, educational, social, and public health issues, and future trends in rheumatology practice. The journal is published by Wiley on behalf of the ACR. For more information, please visit the journal home page at http://wileyonlinelibrary.com/journal/acr.
About Wiley
Wiley is a global provider of content-enabled solutions that improve outcomes in research, education, and professional practice. Our core businesses produce scientific, technical, medical, and scholarly journals, reference works, books, database services, and advertising; professional books, subscription products, certification and training services and online applications; and education content and services including integrated online teaching and learning resources for undergraduate and graduate students and lifelong learners.
Founded in 1807, John Wiley & Sons, Inc. (NYSE: JWa, JWb), has been a valued source of information and understanding for more than 200 years, helping people around the world meet their needs and fulfill their aspirations. Wiley and its acquired companies have published the works of more than 450 Nobel laureates in all categories: Literature, Economics, Physiology or Medicine, Physics, Chemistry, and Peace. Wiley's global headquarters are located in Hoboken, New Jersey, with operations in the U.S., Europe, Asia, Canada, and Australia. The Company's website can be accessed at http://www.wiley.com.
Recommendations guide physicians in treatment of systemic juvenile arthritis
2013-09-24
ELSE PRESS RELEASES FROM THIS DATE:
Warning of potential side effects of a product can increase its sales
2013-09-24
Drug ads often warn of serious side effects, from nausea and bleeding to blindness, even death. New research suggests that, rather than scaring consumers away, these warnings can improve consumers' opinions and increase product sales when there is a delay between seeing the ad and deciding to buy or consume the product.
"Messages that warn consumers about potentially harmful side effects — presumably with the intent to nudge them to act more cautiously — can ironically backfire," says psychological scientist Ziv Carmon of INSEAD in Singapore.
Working with Yael Steinhart ...
Patient heal thyself: Solution to treatment for chronic infections could lie in patient's blood
2013-09-23
1. A recent discovery by scientists at A*STAR's Singapore Institute for Clinical Sciences (SICS), in close collaboration with researchers at the Singapore Immunology Network (SIgN), provides hope for a new personalised treatment strategy that could use a patient's own blood to treat the infection. This could help treat millions of people living with chronic infections such as HIV, Hepatitis B or Hepatitis C. These findings were published in the August 2013 issue of The Journal of Clinical Investigation.
2. Patients suffering from chronic infections often have to undergo ...
Smile!
2013-09-23
A brighter, better, longer-lasting dental implant may soon be on its way to your dentist's office.
Dental implants are posts, usually made of titanium, that are surgically placed into the jawbone and topped with artificial teeth. More than dentures or bridges, implants mimic the look and feel of natural teeth. While most dental implants are successful, a small percentage fail and either fall out or must be removed. A scientist at Michigan Technological University wants to lower that rate to zero using nanotechnology.
"Dental implants can greatly improve the lives of ...
Propofol discovery may help lead to development of new anesthetics
2013-09-23
New research on the most commonly used anaesthetic drug could help to unravel a long-standing mystery about how it induces a pain-free, sleep-like state.
General anaesthetics are administered to tens of millions of people every year in hospitals, where they are used to sedate patients undergoing surgery. Despite this, scientists have yet to understand how the drug interacts with its targets in brain cells to achieve this effect.
Following years of research on propofol, which has become the most commonly used anaesthetic since it was introduced in the 1980s, researchers ...
Immune system fights infection with performance enhancement
2013-09-23
Researchers in Melbourne, Australia, have found that even our immune system is subject to performance enhancement, with our bodies giving immune cells the boost they need to ensure the best team is selected to fight infections.
The discovery could help in developing new treatments for blood diseases such as leukaemia and autoimmune diseases in which the body attacks its own tissues, such as in diabetes or rheumatoid arthritis. It could also be used to enhance immune response to HIV and other chronic infections.
The finding, by researchers at the Walter and Eliza Hall ...
Climate change nothing new in Oz
2013-09-23
While we grapple with the impact of climate change, archaeologists suggest we spare a thought for Aboriginal Australians who had to cope with the last ice age.
"The period scientists call the Last Glacial Maximum, or LGM for short, is the most significant climatic event ever faced by humans on this continent," Associate Professor Sean Ulm from James Cook University in Cairns said.
Research recently published in the Journal of Archaeological Science sheds new light on the ways Aboriginal civilisation met the challenges of extreme climate change during the Last Glacial ...
Richness mapping and prediction of amphibians in Southern and Central China
2013-09-23
Systematic conservation planning is a multiple-objective process. Identification of important areas and species with high conservation priority is two of the research objectives. China is one of mega-biodiversity countries of the world. Along with rapid economic development and environmental degeneration, native and endemic species of China are confronting growing threats in the last two decades. It is an urgent agenda to set up relevant conservation policies, researches and decision supports so as to better reduce extinction risks of vertebrate animals of China.
Amphibians ...
Encouraging outcomes for pediatric brain tumor patients treated with proton therapy
2013-09-23
Atlanta, September 22, 2013—When used to treat pediatric patients with intracranial malignant tumors, proton therapy may limit the toxicity of radiation therapy while preserving tumor control, according to research presented today at the American Society for Radiation Oncology's (ASTRO's) 55th Annual Meeting.
Typically, central nervous system malignancies are treated with surgical resection and post-operative radiation therapy. Proton therapy, an external beam radiation therapy in which protons deliver precise radiation doses to a tumor, offers significant sparing of ...
Sulfasalazine does not reduce diarrhea for patients receiving pelvic radiation therapy
2013-09-23
Atlanta, September 22, 2013—Patients receiving radiotherapy (RT) for cancers in the pelvic region can experience diarrhea, a negative side effect of radiation treatment. Sulfasalazine, an oral tablet used to treat inflammation of the bowels, had been shown in a past trial of 31 patients to decrease diarrhea during pelvic RT (Killic 2001). Sulfasalazine does not reduce diarrhea, according to research presented today at the American Society of Radiation Oncology's (ASTRO's) 55th Annual Meeting. The study also determined that the medication may be associated with a higher ...
Cisplatin combined with high-dose brachytherapy for advanced cervical cancer may be more beneficial
2013-09-23
Atlanta, September 22, 2013 — Adding the chemotherapy drug cisplatin to a treatment plan of radiation therapy (RT) and high-dose-rate brachytherapy (HDRB) for stage IIIB cervical cancer is beneficial, according to research presented today at the American Society for Radiation Oncology's (ASTRO's) 55th Annual Meeting. The study also indicated that the combined treatments produced acceptable levels of toxicity.
The randomized, controlled trial studied a total of 147 women in Brazil with stage IIIB squamous cell cervical cancer. A stage IIIB classification indicates that ...